Start with the cream or injection question
The route matters. A review of topical GHK discusses getting the ingredient through skin's outer layer. It doesn't show what injecting GHK-Cu does in people. A cream paper can't carry an injection claim.
GHK-Cu has no FDA-approved medicine. The FDA also explains that a product's intended use affects its category. Calling something skincare doesn't settle the rules when its claims go beyond appearance.
What licensed review means here
Promise Peptides offers GHK-Cu prescription care through licensed U.S. providers at mypromise.com. A provider assesses the request and can decide against prescribing. Care is limited to U.S. patients, and options depend on the state and treatment. The home-page prescription link leads to its GHK-Cu information.
That describes access. It doesn't add to the evidence for a skin result, and it doesn't turn a compounded medicine into an approved drug. The personal decision and the research question still need their own answers.
A prescription isn't FDA product approval
Compounding means mixing, combining or changing ingredients to make a medicine for a patient's particular needs. It doesn't give that product FDA approval. FDA's guide to compounding risks explains the missing checks:
Before marketing, the agency hasn't checked how well these medicines work, whether they're safe or the quality of their preparation. A prescription doesn't add that assessment.
There's another phrase worth slowing down for. The FDA safety record carries an April 22, 2026 content date. It lists injectable GHK-Cu and Melanotan II under “nominated but withdrawn,” alongside the safety concerns. The nominators took back their requests.
Neither entry supplies a withdrawal date. Withdrawal brings no FDA clearance and no permission to compound. GHK-Cu's non-injectable forms have a separate record, so the injected form's entry can't describe every use of the peptide.
A few questions for the conversation
What was actually tested?
The preparation, route and skin goal need to match the evidence. A finding in cells isn't a result in people. A study of one mixture doesn't establish what a different preparation does.
What remains uncertain?
The discussion can cover possible harms, what a benefit would look like and how a problem would be handled. A clinician can consider your health history; a general guide can't complete that review.
Does location matter?
Yes. HHS explains that licensing across state lines varies. An online visit doesn't create nationwide permission to prescribe. Bright Peptides gives no medical advice, sets no dose and arranges no appointments.